The 340B selling price represents the price communicated to the PVP by the supplier or distributor, which may not match the 340B ceiling price published by HRSA. HRSA's 340B ceiling price for a covered outpatient drug is the source of truth and equals the average manufacturer price (AMP) from the preceding calendar quarter for the smallest unit of measure minus the unit rebate amount (URA); it is published by HRSA in the 340B OPAIS Pricing component. The 340B ceiling price is confidential and proprietary; only authorized users can access it on OPAIS.
WAC Price
Wholesale acquisition cost (WAC) is the price paid by a wholesaler (or direct purchaser) in the United States for drugs purchased from the drug’s manufacturer or supplier.
PVP Contracted Price
Sub-340B Price – Contracted price available to PVP participants, which is below the statutory 340B ceiling price. This price has been negotiated by the Prime Vendor with the manufacturer on behalf of 340B covered entities.
Sub-WAC Price – Contracted price available to PVP participants that are subject to the GPO Prohibition and is below the wholesale acquisition cost (WAC). This price has been negotiated by the Prime Vendor with the manufacturer on behalf of 340B covered entities subject to the GPO Prohibition.
PVP Value-Added Price – May appear in either the 340B or WAC accounts; this contracted price is available to PVP participants for products that are not covered outpatient drugs under the Medicaid Drug Rebate Program. This includes certain vaccines, blood glucose monitoring supplies, and prescription vials and labels, among others. Look for the V+ symbol to identify these products.
